Index | - |
Market Cap | 1.17B |
Enterprise Value | 1.31B |
Income | - |
Sales | - |
Book/sh | -3.19 |
Cash/sh | 2.52 |
Dividend Est. | - |
Dividend TTM | - |
Dividend Ex-Date | - |
Dividend Gr. 3/5Y | - - |
Payout | - |
Employees | - |
IPO | Aug 05, 2026 |
P/E | - |
Forward P/E | - |
PEG | - |
P/S | - |
P/B | - |
P/C | 10.13 |
P/FCF | - |
EV/EBITDA | - |
EV/Sales | - |
Quick Ratio | 9.39 |
Current Ratio | 9.39 |
Debt/Eq | 0.04 |
LT Debt/Eq | 0.02 |
Option/Short | No / Yes |
EPS (ttm) | - |
EPS next Y | - |
EPS next Q | -0.56 |
EPS this Y | - |
EPS next Y | - |
EPS next 5Y | - |
EPS past 3/5Y | - - |
Sales past 3/5Y | - - |
EPS Y/Y TTM | - |
Sales Y/Y TTM | - |
EPS Q/Q | - |
Sales Q/Q | - |
| |
| |
Insider Own | 40.01% |
Insider Trans | 18.33% |
Inst Own | 15.65% |
Inst Trans | 9.97% |
ROA | - |
ROE | - |
ROIC | - |
Gross Margin | - |
Oper. Margin | - |
Profit Margin | - |
SMA20 | 20.85% |
SMA50 | 21.10% |
SMA200 | 21.10% |
Trades | |
Shs Outstand | 45.65M |
Shs Float | 27.39M |
| |
| |
| |
52W High | 26.07 -2.01% |
52W Low | 16.15 58.20% |
Volatility | 10.90% 11.19% |
ATR (14) | 2.30 |
RSI (14) | 63.27 |
Beta | - |
Rel Volume | 0.66 |
Avg Volume | 470.59K |
Volume | 311,049 |
Perf Week | 23.43% |
Perf Month | 25.37% |
Perf Quarter | - |
Perf Half Y | - |
Perf YTD | 21.67% |
Perf Year | - |
Perf 3Y | - |
Perf 5Y | - |
Perf 10Y | - |
| |
| |
Prev Close | 24.20 |
Price | 25.55 |
Change % | 5.58% |
|
 |
|
|
|
| |
| Date |
Action |
Analyst |
Rating Change |
Price Target Change |
| Aug-31-26 | Initiated |
RBC Capital Mkts |
Outperform |
$45 |
| Aug-31-26 | Initiated |
Morgan Stanley |
Overweight |
$39 |
| Aug-31-26 | Initiated |
Leerink Partners |
Outperform |
$52 |
| Aug-31-26 | Initiated |
Citigroup |
Buy |
$30 |
|
|
|
Sep-03-26 04:05PM
|
|
|
Sep-02-26 04:05PM
|
|
|
Aug-31-26 09:45AM
|
|
|
Aug-26-26 11:13AM
|
|
|
Aug-24-26 03:01PM
|
|
| 02:21PM |
Loading… |
|
Aug-20-26 02:21PM
|
|
|
Aug-06-26 04:05PM
|
|
|
05:57AM
|
|
|
|
|
|
Attovia Therapeutics, Inc. is a biopharmaceutical company developing precision multispecific biologics to address immune-mediated and inflammatory diseases, including dermatology conditions such as atopic dermatitis and chronic pruritus, and gastroenterology disorders like inflammatory bowel disease. The company is based in San Carlos, CA. The company utilizes its proprietary Attobody platform to design novel multispecific molecules that inhibit multiple disease-driving pathways. Key pipeline candidates include ATTO-1310 (anti-IL31) and ATTO-3712 (anti-IL31 x IL13), both in phase 1 clinical trials for chronic pruritus and inflammatory skin disease, and ATTO-1091, a trispecific molecule in IND-enabling stages for inflammatory bowel disease. The company was founded in 2022 by Petter Veiby, Tao Fu, Zaneta Odrowaz. Tao Fu has been the CEO of the company since 2022. | | M.S.Mr. Tao Fu M.B.A. Chief Scientific OfficerDr. Petter Veiby Ph.D. M.P.H.Dr. Hubert C. Chen M.D. Chief Financial OfficerMr. Steven Chan CPA Chief Technology OfficerDr. Hangjun Zhan Ph.D. |
|
|
| |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| GOLDMAN SACHS GROUP INC | Former 10% Owner | Aug 05 '26 | Proposed Sale | 21.00 | 105,807 | 2,221,947 | | Aug 28 05:50 PM | | WALSH COLIN | Director | Aug 06 '26 | Buy | 17.00 | 500,000 | 8,500,000 | 3,020,632 | Aug 13 09:52 PM | | WALSH COLIN | Director | Aug 05 '26 | Buy | 21.00 | 85,000 | 1,785,000 | 85,000 | Aug 13 09:52 PM | | WALSH COLIN | Director | Aug 05 '26 | Sale | 21.28 | 105,807 | 2,251,658 | 0 | Aug 13 09:52 PM | | GOLDMAN SACHS GROUP INC | Former 10% Owner | Aug 06 '26 | Buy | 17.00 | 500,000 | 8,500,000 | 3,020,632 | Aug 13 09:51 PM | | GOLDMAN SACHS GROUP INC | Former 10% Owner | Aug 05 '26 | Buy | 21.00 | 85,000 | 1,785,000 | 85,000 | Aug 13 09:51 PM | | GOLDMAN SACHS GROUP INC | Former 10% Owner | Aug 05 '26 | Sale | 21.28 | 105,807 | 2,251,658 | 0 | Aug 13 09:51 PM | | venBio Global Strategic Fund I | 10% Owner | Aug 06 '26 | Buy | 17.00 | 382,352 | 6,499,984 | 4,181,367 | Aug 10 04:12 PM | | Redmile Group, LLC | 10% Owner | Aug 06 '26 | Buy | 17.00 | 400,000 | 6,800,000 | 1,182,854 | Aug 07 09:47 PM | | Redmile Group, LLC | 10% Owner | Aug 06 '26 | Buy | 17.00 | 200,000 | 3,400,000 | 982,854 | Aug 07 09:47 PM | | Sanofi | 10% Owner | Aug 06 '26 | Buy | 17.00 | 300,000 | 5,100,000 | 1,082,855 | Aug 07 03:45 PM | | Frazier Life Sciences XI, L.P. | 10% Owner | Aug 06 '26 | Buy | 17.00 | 588,235 | 9,999,995 | 6,154,213 | Aug 06 05:35 PM |
|
|
A